Cancer Metabolism Approach Uncovers Drug Target, Biomarker
This article was originally published in Start Up
Executive Summary
Scientists at Agios Pharmaceuticals have shown that a mutated metabolic enzyme common to many brain cancers acts like an oncogene, reversing the previously held belief that it was not involved in cancer-causing activity. They also linked the mutation, IDH1, to a potential predictive biomarker for glioma patients. Their work helps validate a drug discovery apporach based on the study of proliferating cancer cell metabolism.
You may also be interested in...
Biotechs Target Cancer Metabolism
As reseachers uncover linkages between tumor formation and cellular metabolism, start-ups and their venture backers see an opportunity to create a new class of cancer medicines. In this issue, we profile Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals.
Biotechs Target Cancer Metabolism
As reseachers uncover linkages between tumor formation and cellular metabolism, start-ups and their venture backers see an opportunity to create a new class of cancer medicines. In this issue, we profile Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals.
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.